Inhibitex Completes Phase I Clinical Trials for FV-100 and Selects Lead HCV Compounds for Advanced Preclinical Studies. Business Wire | February 9, 2009 | COPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information) Copyright

Favorable Safety and Pharmacokinetic Data Support Evaluation of Once-Daily Dosing of FV-100 in Phase II

ATLANTA -- Inhibitex, Inc. (NASDAQ: INHX), a biopharmaceutical company focused on the development of products to treat serious infectious diseases, reported today that it has completed its Phase I clinical trials of FV-100, a highly potent and fast-acting oral compound being developed to treat shingles (herpes zoster). The recently completed trials include both a multiple ascending dose study in subjects aged 18-55 and a separate study conducted in subjects 65 ...

Related newspaper, magazine, and trade journal articles from HighBeam Research

(Including press releases, facts, information, and biographies)

	Inhibitex Reports Initiation of Multiple Ascending Dose Trial of FV-100 for Shingles. Business Wire ; ...completed a Phase I single ascending dose (SAD) clinical trial and initiated a multiple ascending dose (MAD) trial of FV-100, a highly potent...results of the multiple ascending dose trial, we plan to advance FV-100 into a well powered...
	Inhibitex Initiates Phase I Trial of FV-100 for the Treatment of Shingles. Business Wire ; ...in-man single ascending dose trial of three lower doses of FV-100 (10, 20 and...conduct a multiple ascending dose study of FV-100 in the third...s goal to advance FV-100 into a multiple ascending dose trial later this...
	Inhibitex Finalizes Phase I Clinical Trials for FV-100. Magazine article from: Health & Beauty Close-Up ; ...placebo controlled multiple ascending dose trial was designed to...of five oral doses of FV-100 (100, 200, 400...and pharmacokinetics of FV-100 in older individuals...s single and multiple ascending dose Phase I trials. The...adverse events reported and FV-100 appeared to be...
	Inhibitex Presents Encouraging Phase I Data on FV-100 At 21st International Conference on Antiviral Research.(Conference news) Business Wire ; ...from a Phase I clinical study of FV-100, a highly potent antiviral...safety data from our initial single ascending dose study of FV-100 in healthy volunteers...pharmacokinetic data suggest that FV-100, which is a prodrug, is...
	Inhibitex Reports Favorable Results from First Clinical Trial of FV-100.(Clinical report) Business Wire ; ...initial Phase I clinical trial of FV-100, a nucleoside analogue...placebo-controlled single ascending dose study, which was conducted...pharmacokinetics of three oral doses of FV-100 (10, 20 and 40 mg...of six subjects that received FV-100 and two that received...
	(99m)Tc-labeled divalent and tetravalent CC49 single-chain Fv's: Novel imaging agents for rapid in vivo localization of human colon carcinoma Magazine article from: The Journal of Nuclear Medicine ; ...techniques have allowed the design of single-chain Fv's (scFv's) of monoclonal antibodies (mAbs...suitable radionuclide. Methods: Divalent (sc(Fv)^sub 2^) and tetravalent ([sc(Fv)^sub 2]2^) scFv's of mAb CC49 were evaluated...
	Inhibitex Initiates Phase II Clinical Trial of FV-100 for the Treatment of Shingles. Business Wire ; ...initiated a Phase II clinical trial with FV-100, its oral antiviral compound in clinical...controlled, double-blind study evaluating FV-100 against an active control (valacyclovir...to one of three treatment arms: 200 mg FV-100 administered once daily; 400 mg FV...
	Preclinical Data on FermaVir's FV-100 Presented at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy.(Conference news) Business Wire ; ...presented data from preclinical studies for FV-100, a highly potent, orally bioavailable...antiviral and pharmacokinetic properties for FV-100, including the compound's bioavailability...Zoster Virus (VZV). "These data on FV-100 provide further evidence of the compound...
	Structural analysis of anti-HIV monoclonal antibody 447-52D Fv feasible. Newspaper article from: Biotech Week ; ...anti-HIV monoclonal antibody 447-52D Fv is feasible, thanks to a novel E. coli-based expression model. "The Fv is the smallest antigen binding fragment...researchers in Israel explained. "The 26-kDa Fv is amenable for structure determination...
	Cepheid Receives FDA Clearance for Xpert[R] HemosIL[R] FII & FV Test. Newspaper article from: Blood Weekly ; ...to market its Xpert HemosIL FII & FV test. The test detects Factor II (FII) and Factor V Leiden (FV) genetic variations associated with thrombophilia...thrombosis). Xpert HemosIL FII & FV delivers results in just over thirty minutes...

For more facts and information, see all results

Find more facts and information related to the article "Inhibitex Completes Phase I Clinical Trials for ..."